High dose of dexamethasone attenuates docetaxel-induced fluid retention in breast cancer treatment
Abstract Docetaxel-induced fluid retention (DIFR) cumulatively occurs and is one of the most troublesome adverse effects. This study aimed to determine whether high dose dexamethasone (DEX) could prevent DIFR during breast cancer treatment. Breast cancer patients receiving docetaxel (75 mg/m2)-conta...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-06-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-023-36264-4 |
| _version_ | 1797806721471610880 |
|---|---|
| author | Yoshitaka Saito Ryota Kanno Yoh Takekuma Takashi Takeshita Tomohiro Oshino Mitsuru Sugawara |
| author_facet | Yoshitaka Saito Ryota Kanno Yoh Takekuma Takashi Takeshita Tomohiro Oshino Mitsuru Sugawara |
| author_sort | Yoshitaka Saito |
| collection | DOAJ |
| description | Abstract Docetaxel-induced fluid retention (DIFR) cumulatively occurs and is one of the most troublesome adverse effects. This study aimed to determine whether high dose dexamethasone (DEX) could prevent DIFR during breast cancer treatment. Breast cancer patients receiving docetaxel (75 mg/m2)-containing regimens were divided into 4 and 8 mg/day DEX groups, with each DEX dose administered on days 2–4 and retrospectively assessed. Incidence of greater than or equal to grade 2 DIFR was significantly lower in the 8 mg group (13.0%) compared to the 4 mg group (39.6%, P = 0.001). All-grade DIFR was also less in the 8 mg group (P = 0.01). Furthermore, the maximum variation of body weight was significantly lower in the 8 mg group (P = 0.0003). These results were also confirmed in the propensity score-matched population. Additionally, time-related DIFR incidence was also significantly delayed in the 8 mg group (P = 0.0005). Our study revealed that high dose DEX prevents DIFR. Therefore, further studies on its management are required for less onerous chemotherapy provision with better DIFR control. |
| first_indexed | 2024-03-13T06:11:35Z |
| format | Article |
| id | doaj.art-881e8e8c97154e808f55be54608079a7 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-03-13T06:11:35Z |
| publishDate | 2023-06-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-881e8e8c97154e808f55be54608079a72023-06-11T11:14:52ZengNature PortfolioScientific Reports2045-23222023-06-011311910.1038/s41598-023-36264-4High dose of dexamethasone attenuates docetaxel-induced fluid retention in breast cancer treatmentYoshitaka Saito0Ryota Kanno1Yoh Takekuma2Takashi Takeshita3Tomohiro Oshino4Mitsuru Sugawara5Department of Pharmacy, Hokkaido University HospitalDepartment of Pharmacy, Hokkaido University HospitalDepartment of Pharmacy, Hokkaido University HospitalDepartment of Breast Surgery, Hokkaido University HospitalDepartment of Breast Surgery, Hokkaido University HospitalDepartment of Pharmacy, Hokkaido University HospitalAbstract Docetaxel-induced fluid retention (DIFR) cumulatively occurs and is one of the most troublesome adverse effects. This study aimed to determine whether high dose dexamethasone (DEX) could prevent DIFR during breast cancer treatment. Breast cancer patients receiving docetaxel (75 mg/m2)-containing regimens were divided into 4 and 8 mg/day DEX groups, with each DEX dose administered on days 2–4 and retrospectively assessed. Incidence of greater than or equal to grade 2 DIFR was significantly lower in the 8 mg group (13.0%) compared to the 4 mg group (39.6%, P = 0.001). All-grade DIFR was also less in the 8 mg group (P = 0.01). Furthermore, the maximum variation of body weight was significantly lower in the 8 mg group (P = 0.0003). These results were also confirmed in the propensity score-matched population. Additionally, time-related DIFR incidence was also significantly delayed in the 8 mg group (P = 0.0005). Our study revealed that high dose DEX prevents DIFR. Therefore, further studies on its management are required for less onerous chemotherapy provision with better DIFR control.https://doi.org/10.1038/s41598-023-36264-4 |
| spellingShingle | Yoshitaka Saito Ryota Kanno Yoh Takekuma Takashi Takeshita Tomohiro Oshino Mitsuru Sugawara High dose of dexamethasone attenuates docetaxel-induced fluid retention in breast cancer treatment Scientific Reports |
| title | High dose of dexamethasone attenuates docetaxel-induced fluid retention in breast cancer treatment |
| title_full | High dose of dexamethasone attenuates docetaxel-induced fluid retention in breast cancer treatment |
| title_fullStr | High dose of dexamethasone attenuates docetaxel-induced fluid retention in breast cancer treatment |
| title_full_unstemmed | High dose of dexamethasone attenuates docetaxel-induced fluid retention in breast cancer treatment |
| title_short | High dose of dexamethasone attenuates docetaxel-induced fluid retention in breast cancer treatment |
| title_sort | high dose of dexamethasone attenuates docetaxel induced fluid retention in breast cancer treatment |
| url | https://doi.org/10.1038/s41598-023-36264-4 |
| work_keys_str_mv | AT yoshitakasaito highdoseofdexamethasoneattenuatesdocetaxelinducedfluidretentioninbreastcancertreatment AT ryotakanno highdoseofdexamethasoneattenuatesdocetaxelinducedfluidretentioninbreastcancertreatment AT yohtakekuma highdoseofdexamethasoneattenuatesdocetaxelinducedfluidretentioninbreastcancertreatment AT takashitakeshita highdoseofdexamethasoneattenuatesdocetaxelinducedfluidretentioninbreastcancertreatment AT tomohirooshino highdoseofdexamethasoneattenuatesdocetaxelinducedfluidretentioninbreastcancertreatment AT mitsurusugawara highdoseofdexamethasoneattenuatesdocetaxelinducedfluidretentioninbreastcancertreatment |